Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.43+0.12 (+3.63%)
Close on Nov 18, 2026Market cap $31.84MP/E –Yield –
Exozymes net income
Net income is the profit left for shareholders after every expense, interest and tax.
Exozymes's net income for the twelve months ending Sep 30, 2026 was -$10.14M. For fiscal 2025 it was -$9.16M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.16M | – |
| FY2024 | Dec 31, 2024 | -$5.86M | – |
| FY2023 | Dec 31, 2023 | -$2.04M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$520.60K | – |
| Q2 FY2023 | Jun 30, 2023 | -$178.08K | – |
| Q1 FY2023 | Mar 31, 2023 | -$241.15K | – |
See a number that looks wrong?